Mayo Clinic Proceedings
- Print ISSN
- Electronic ISSN
- Impact factor
- Usage rank
- Article count
- Free count
- Free percentage
- PDFs via platforms
- Mayo, Ama, Gale, Nephrology, Highwire from 1995, Endocrine, CSA, Sciencedirect from 1995, The Mayo Foundation for Medical Education and Research., Aacr, Csh, Proquest, Mdconsult from 2006, Ovid from 2002, Rupress, and Aaas
The quest to prove endovascular stroke therapy: searching for the "sweet spot" in patient selection.
Reversal of medical practices.
In reply I-reversal of medical practices.
Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome.
Restless legs syndrome (RLS)/Willis-Ekbom disease (WED) is a common disorder, occurring at least twice a week and causing at least moderate distress in 1.5% to 2.7% of the population. It is important for primary care physicians to be familiar with this disorder and its management. Much has changed i...
Stamp vignette on medical science. Vincent du Vigneaud-Nobel Prize in chemistry.
Iris, sunglass lens, black bulb and mirage morning by james rosenquist.
Institution-wide QT alert system identifies patients with a high risk of mortality.
To determine the phenotype and outcome of patients with QTc of at least 500 ms and to create a pro-QTc risk score for mortality. An institution-wide computer-based QT alert system was developed and implemented at Mayo Clinic in Rochester, Minnesota. This system screens all electrocardiograms (ECGs)...
Maximal estimated cardiorespiratory fitness, cardiometabolic risk factors, and metabolic syndrome in the aerobics center longitudinal study.
We performed a cross-sectional analysis of 38,659 Aerobics Center Longitudinal Study participants seen between January 1, 1979, and December 31, 2006, to examine CRF levels defined as low (lower 20%), moderate (middle 40%), and high (upper 40%) of age- and sex-specific distributions vs National Chol...
Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-t...
We used a deidentified pharmacy claims database identifying patients prescribed dasatinib, erlotinib, everolimus, imatinib, lapatinib, nilotinib, pazopanib, sorafenib, or sunitinib between January 1, 2008, and May 31, 2010. Coprescribing was 1 or more overlapping days of supply between the OAD and p...
Association of Angiotensin-converting enzyme inhibitor therapy initiation with a reduction in hemoglobin levels in patients without renal fa...
To investigate whether treatment initiated with an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB) for patients with ischemic heart disease, hypertension, or diabetes causes a reduction in hemoglobin (Hb) levels. This was a retrospective cohort analysis us...